[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000209:etiology / Q000628:therapy*; D000069059:Atorvastatin; D018450:Disease Progression; D005080:Exercise Test / Q000187:drug effects; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000209:etiology / Q000628:therapy*; D007581:Jejunoileal Bypass; D017035:Pravastatin / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D019821:Simvastatin / Q000627:therapeutic use; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin; D017035:Pravastatin
Stellenwert der Therapie der Hyperlipoproteinämie bei Patienten mit peripherer arterieller Verschlusskrankheit.